Informazioni
After qualifying in medicine and surgery in 1986, Professor Bridgewater specialised in medical oncology at the Middlesex, Mount Vernon and Royal Marsden Hospitals. He gained a PhD in gene therapy at the Institute of Cancer Research and took a senior lecturer position in medical oncology at UCL and UCLH in 1999.
Professor Bridgewater leads the National Cancer Research Institute (NCRI) Study Group upper gastrointestinal malignancy and the Genomics England Upper Gastrointestinal Workstream, focusing on clinical and scientific research in gastrointestinal cancer. He has led and contributed to landmark studies in gastrointestinal malignancy that have defined the international standard of care of patients with gastrointestinal cancer over the last 20 years.
Our increasing knowledge of the scientific basis of cancer is making personalised oncology treatment a reality. The discovery of faulty genes in cancers that lead to cancer growth has in turn led to the development of novel therapies to target them. An example of this is Professor Bridgewater's work with AMMF, the cholangiocarcinoma charity, championing the case for personalised therapy on cancer (see Molecular Profiling: booklet and video - AMMF).
Through close collaboration with the North Thames Genomic Laboratory Hub at the Royal Marsden and the HCA Genomic laboratories, Professor Bridgewater has been able to deliver personalised cancer treatment using such novel targeted therapies, both bespoke and as part of clinical trials or indeed both. This allows patients to receive treatment that is focussed on the genomic abnormalities of their own cancer and therefore can be more effective and spares the side effects of non-targeted treatments like chemotherapy.
Professor Bridgewater has served on several national and international committees including the Clinical Trials Advisory and Awards Committee (CTAAC), the National Institute for Health and Care Excellence committee (NICE), the American Society of Clinical Oncology (ASCO) faculty, the National Institute of Health and Medical Research (INSERM), France and the French National Cancer Institute (INCa). This work permits an understanding of the many constantly advancing aspects of cancer research.
Specialties
• Upper Gastrointestinal (GI) Service
Research interests
Professor Bridgewater's research interests are based around clinical trials offering novel and potentially more effective therapies to patients. He also has multiple laboratory-based collaborations with colleagues nationally and internationally, investigating the reasons why treatments work in order to design more effective strategies.
Diseases, Medical Tests and Treatments
Chemotherapy
Bilary Cancer
Bowel Cancer
Cancer Unknown Primary
Gastro-intestinal Cancers
Liver Cancer
Professor Bridgewater leads the National Cancer Research Institute (NCRI) Study Group upper gastrointestinal malignancy and the Genomics England Upper Gastrointestinal Workstream, focusing on clinical and scientific research in gastrointestinal cancer. He has led and contributed to landmark studies in gastrointestinal malignancy that have defined the international standard of care of patients with gastrointestinal cancer over the last 20 years.
Our increasing knowledge of the scientific basis of cancer is making personalised oncology treatment a reality. The discovery of faulty genes in cancers that lead to cancer growth has in turn led to the development of novel therapies to target them. An example of this is Professor Bridgewater's work with AMMF, the cholangiocarcinoma charity, championing the case for personalised therapy on cancer (see Molecular Profiling: booklet and video - AMMF).
Through close collaboration with the North Thames Genomic Laboratory Hub at the Royal Marsden and the HCA Genomic laboratories, Professor Bridgewater has been able to deliver personalised cancer treatment using such novel targeted therapies, both bespoke and as part of clinical trials or indeed both. This allows patients to receive treatment that is focussed on the genomic abnormalities of their own cancer and therefore can be more effective and spares the side effects of non-targeted treatments like chemotherapy.
Professor Bridgewater has served on several national and international committees including the Clinical Trials Advisory and Awards Committee (CTAAC), the National Institute for Health and Care Excellence committee (NICE), the American Society of Clinical Oncology (ASCO) faculty, the National Institute of Health and Medical Research (INSERM), France and the French National Cancer Institute (INCa). This work permits an understanding of the many constantly advancing aspects of cancer research.
Specialties
• Upper Gastrointestinal (GI) Service
Research interests
Professor Bridgewater's research interests are based around clinical trials offering novel and potentially more effective therapies to patients. He also has multiple laboratory-based collaborations with colleagues nationally and internationally, investigating the reasons why treatments work in order to design more effective strategies.
Diseases, Medical Tests and Treatments
Chemotherapy
Bilary Cancer
Bowel Cancer
Cancer Unknown Primary
Gastro-intestinal Cancers
Liver Cancer
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Professor John Bridgewater
Istruzione e formazione
-
2011–2017 MD · Medicine and Surgery
-
2017–2021 Residency · Oncologia
-
2021–2022 Fellowship · Subspecialty training
Carriera e incarichi
-
2021-09–2022-08 Junior consultant
Licenze e assicurazione
Licenze mediche
GB — Organización Médica Colegial de España (OMC)
Certificazioni di specializzazione
European Board of Oncologia
Assicurazione responsabilità professionale:
Generali Healthcare · 4,000,000 EUR copertura · No claims on file
Procedure eseguite
| Procedura | Codice | Conteggio totale |
|---|---|---|
| GP consultation | 99213 | 337 |
| Annual physical exam | 99395 | 1,799 |
| Vaccination administration | 90471 | 1,455 |
| Minor procedure (skin) | 17110 | 2,992 |
Servizi e prezzi
| Servizio | Durata | Modalità | Prezzo |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 90 min | in_clinic | 720.00 EUR |
| Minor procedure (skin) | 60 min | in_clinic | 630.00 EUR |
Studio, team e in pratica
Video
Ricerca e pubblicazioni
indice h: 8 · i10: 11
-
European registry analysis of Oncologia outcomes
DOI: 10.1634/euroclin.2025.0 · PMID: 31077188 · citato da 121
-
Outcomes of Oncologia in adults — a multi-centre cohort
DOI: 10.8431/euroclin.2024.1 · PMID: 36677704 · citato da 59
Conferenze su invito
- Practical updates in Oncologia European Annual Congress (Oncologia) · Vienna · 2024 · invited
- Single-centre experience in Oncologia National Society Meeting · London · 2023 · oral abstract
Premi e affiliazioni
Premi
- 🏆 Top-rated Oncologia — London · EuroClinics Patient Choice · 2025 · regional
Iscrizioni a società
- WONCA Europe — Family Doctors — Member · Dal 2022
- national college of family doctors — Member · Dal 2022
- European Union of Medical Specialists (UEMS) — Member · Dal 2022
Articoli di questo medico
- Patient education Patient guide to Oncologia
- Awareness When should you see a oncologia?
Per pazienti internazionali
- Coordinatore
- Patient liaison · professor.john.bridgewater@euroclinics.example
Posizione
1 tagRecensioni dei pazienti
Condividi la tua esperienza — aiuta altri pazienti a trovare il medico giusto. Scrivi una recensione →
Recensioni recenti
-
★★★★★ ✓ Verificato Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.
-
★★★★★ ✓ Verificato Took time to listen and reviewed all my previous results. I would absolutely recommend.
-
★★★★☆ ✓ Verificato Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.
Specialisti simili
Sfoglia tutti →
Mr Abdulla Alhasso
Oncologia · Glasgow
Dr Alexander McDonald
Oncologia · Glasgow
Dr Amna Sheri
Oncologia · London
Dr Angus Robinson
Oncologia · Horley
Dr Anne Armstrong
Oncologia · Manchester
Dr Ashraf Azzabi
Oncologia · Washington
Dr Clare Green
Oncologia · Winchester
Dr Desmond Yip
Oncologia · Garran